

**PA Health & Wellness Pharmacy and Therapeutics Committee Meeting Minutes**  
**300 Corporate Center Drive, Suite 600, Camp Hill, PA 17011**

**Wednesday, July 21, 2021 – 12:00 PM – 1:30 PM**

**Present:** Meghan McNelly, PharmD, MHA; FACHE, Dr. Venkateswara Davuluri, Michelle Bennett, RPh, Debbie Rose (Participant Advisory), Germaine Biksey, Jill Schaeffer, RN, Dr. Mahmood Usman, Dr. Kolin Good, Dr. Christopher Hughes, Dr. Keith Brown, Dr. Carla Huitt

**Absent:**

**Guests:** William Baker (Pharmacy), Christina Kauffman (Pharmacy), Amy Nowacki (Pharmacy), Tanayja Sams (Pharmacy), Rhonda Hredzak (Pharmacy), Jason Skaria (Pharmacy Manager), Shalyn Kline (Pharmacy), Jennifer Shepard (Manager Clinical Pharmacy Solutions Medicare), George Kimbrow, Jr. (PHW Policy Coordinator), Marci Kramer (QI Director), Michael Volstorf (Clinical Pharmacist, MED-Pharmacy), Heather Clarke (Program Director and Behavioral Health Liaison), Jacci Rowe (Director, Compliance), Shirley Stahler

**Call to Order:** The PA Health & Wellness Pharmacy and Therapeutics Committee meeting called to order at 12:02 PM.

**Adjourned:** The PA Health & Wellness Pharmacy and Therapeutics Committee meeting was adjourned at 12:28 PM.

**Next Meeting:** Wednesday, October 20, 2021 – 12:00 PM

**Submitted By:** William Baker (PHW Pharmacy)

**Date:** July 23, 2021

**Committee Chair:** \_\_\_\_\_

Meghan McNelly, PharmD, MHA; FACHE

**CONFIDENTIAL** Notice: This document comprises the confidential investigations, proceedings, and/or records of a medical review Committee and is not subject to discovery or introduction into evidence in any civil or administrative action. This document contains information deemed confidential by the health care quality improvement act of 1986 (42 U.S.C.S.ξ1137 (b)).

Agenda Item	Discussion/Recommendation	Action	Next Steps	Owner
I. Introduction & Call to Order	Meghan McNelly called the PA Health & Wellness Pharmacy & Therapeutics Committee meeting to order at 12:02 PM.	Meeting Called to Order		Meghan McNelly
A. Introductions	Dr. Keith Brown – <i>Magellan Health</i> Introduced as new Committee Member.	Introductions were made.		Meghan McNelly
B. Announcements	<p>Meghan reminded all that 75% attendance is required for all voting members to remain as active committee members.</p> <p>There will be a statewide review the beginning of September. Let Meghan know if there are any questions.</p>	No action required or taken.		Meghan McNelly
C. Explanation of the Review and Approval Process	<ul style="list-style-type: none"> <li>i. Voting and vote totals</li> <li>ii. Tie breaker</li> <li>iii. Pennsylvania’s Review and Approval Process</li> </ul> <p>Meghan informed the Committee that from this point forward the voting will be done differently. Roll call will be taken and for each vote the voting members will be asked if there are any objections. If there are no objections, the vote will pass.</p>	No action required or taken.		Meghan McNelly
D. Charter Review	The committee charter was reviewed with the committee members.	No action required or taken.		Meghan McNelly
II. Approval of Meeting Minutes	A vote was taken for the approval of the minutes from Q2_2021. No objections were made.	Adoption of Q2_2021 Meeting Minutes		Bill Baker

**CONFIDENTIAL** Notice: This document comprises the confidential investigations, proceedings, and/or records of a medical review Committee and is not subject to discovery or introduction into evidence in any civil or administrative action. This document contains information deemed confidential by the health care quality improvement act of 1986 (42 U.S.C.S. §1137 (b)).

		recorded as approved		
<b>III. Old Business</b>				
A. Policy Submission Status	All outstanding clinical policies are now approved.	No action required or taken.		Bill Baker/Meghan McNelly
<b>New Business</b>				
A. Statewide PDL updates	<p>A report was sent to the State so they can verify compliance.</p> <p>PHW received feedback from OLTL on the report. The grandfathered status that did not move to preferred was overturned. A medical review of some of the grandfathered was performed and some were found that the not preferred was the best option for the Participant.</p> <p>There was a very small number of claims for a lot of the categories which made the numbers fall under the 95%. Overall we are above the 95% threshold.</p>			Meghan McNelly
B. Cystic Fibrosis provider Education	Voting members were asked if there were any objections to the Education. No opposition was expressed.	The education was Committee approved.		Bill Baker
C. FDA Updates	This is informational only and addresses recalls, new drugs, etc. No vote necessary.	Informational		Bill Baker
D. Drug Coverage Criteria	<ol style="list-style-type: none"> <li>1. Medicaid Summary Table             <ol style="list-style-type: none"> <li>a. 45 clinical policies                 <ol style="list-style-type: none"> <li>i. 12 new policies created or revisions</li> </ol> </li> </ol> </li> <li>2. Ambetter</li> </ol>	The policy revisions were Committee approved.		Bill Baker

**CONFIDENTIAL** Notice: This document comprises the confidential investigations, proceedings, and/or records of a medical review Committee and is not subject to discovery or introduction into evidence in any civil or administrative action. This document contains information deemed confidential by the health care quality improvement act of 1986 (42 U.S.C.S. §1137 (b)).

	<p>a. 127 policies b. 44 policies with substantial changes</p> <p>Voting members were asked if there was any objection to the changes. No objections expressed.</p>			
E. Ambetter	<p>Proposed Prior Authorization Auto-Renewal List. This is a proposed list of medications the approval tier structure would be removed to streamline the process. This would be less work for the providers.</p> <p>Bill ask if there were any objections to this process. No objections were expressed.*</p> <p>*Please note the following recusals from participation in voting and discussion:</p> <ul style="list-style-type: none"> <li>• Dr Kolin Good: <ul style="list-style-type: none"> <li>○ CP.PHAR.424 Faslodex</li> <li>○ CP.PMN.163 Lokelma</li> <li>○ CP.PMN.46 Daliresp</li> </ul> </li> </ul>	The process was Committee approved.		Bill Baker
F. Complaints and Grievances Review	<p>The Committee was informed that the recurring opioids are taking a downward trend.</p> <p>In the 2<sup>nd</sup> quarter there were 22 determinations. Out of these 5 were upheld, 5 were overturned, and 12 were withdrawn pre-grievance.</p>			
G. PBM Oversight	<p>In the 2<sup>nd</sup> quarter, there were 120 requests audited. (60 approvals, 60 denials).</p>			Meghan McNelly

**CONFIDENTIAL** Notice: This document comprises the confidential investigations, proceedings, and/or records of a medical review Committee and is not subject to discovery or introduction into evidence in any civil or administrative action. This document contains information deemed confidential by the health care quality improvement act of 1986 (42 U.S.C.S.ξ1137 (b)).

	<p>Findings were 5 requests had denial language that was not at a 6<sup>th</sup> grade level. There were 3 requests that were denied by a RPh instead of a physician. One request the wrong policy was utilized.</p> <p>Coaching was completed with the Envolve clinical reviewers to address the issues.</p>			
<p>H. Medicare Pharmacy Updates</p>	<p>Jennifer Shepard presented the Quality Measures for Medicare Part D.</p> <ul style="list-style-type: none"> <li>• Statin use in Patients with ASCVD – 82% compliant.</li> <li>• Statin use in Patients with Diabetes – 85% compliant.</li> <li>• Patient Medication Adherence – Three classes of medication. <ul style="list-style-type: none"> <li>- RAS antagonist adherence – 93%</li> <li>- Diabetes medication adherence – 93%</li> <li>- Statin adherence – 94%</li> </ul> </li> <li>• Complaints and Grievances <ul style="list-style-type: none"> <li>- 18 filed since mid-May for copay, formulary issues, and coordination of Benefits.</li> <li>- 17 Resolved.</li> </ul> </li> <li>• Pharmacy Triage – Inquiries including drug information, prior authorization questions, medication reviews, polypharmacy, adverse drug reactions, drug-drug interactions, etc. <ul style="list-style-type: none"> <li>- Q2 Technician inquiries – 44</li> <li>- Pharmacist inquiries - 41</li> </ul> </li> <li>• FWA <ul style="list-style-type: none"> <li>- One pharmacy referred to Special Investigations for suspected fraud. Pending further investigation.</li> </ul> </li> <li>• Adherence to Antipsychotic Medications for Schizophrenia <ul style="list-style-type: none"> <li>- Working with Community Behavioral Health and other MCO's to create member and provider outreach material</li> <li>- Outreach to providers</li> <li>- Send member education</li> <li>- Goal is to outreach to providers by October</li> </ul> </li> </ul>			<p>Jennifer Shepard</p>

**CONFIDENTIAL** Notice: This document comprises the confidential investigations, proceedings, and/or records of a medical review Committee and is not subject to discovery or introduction into evidence in any civil or administrative action. This document contains information deemed confidential by the health care quality improvement act of 1986 (42 U.S.C.S.ξ1137 (b)).

I. COVID 19 Response	Continuing point-of-sale edits for “refill too soon”. Continuing quantity limits for hydroxychloroquine for members without a valid non-COVID –related diagnosis, and late refill reporting. The late refill reporting is sent to the Service Coordinators.  Commercials featuring NFL players giving reasons to get the vaccine.	No action required or taken.		Meghan McNelly
J. Help Wanted	<ul style="list-style-type: none"> <li>Participant member</li> </ul>			
K. Open Forum	Nothing discussed.	No action required or taken.		Meghan McNelly
Adjournment	The meeting was adjourned at 12:28 pm	Meeting adjourned		Meghan McNelly

**CONFIDENTIAL** Notice: This document comprises the confidential investigations, proceedings, and/or records of a medical review Committee and is not subject to discovery or introduction into evidence in any civil or administrative action. This document contains information deemed confidential by the health care quality improvement act of 1986 (42 U.S.C.S. §1137 (b)).